Phase I Visceral Fat Reduction -- 14.3% reduction in visceral fat and a 3.3% reduction in waist circumference observed following a single dose of 007. MASH (Metabolic Dysfunction-Associated Steatohepatitis) : A severe form of non-alcoholic fatty liver disease characterized by liver inflammation and damage. Early follow-up from our 400-milligram cohort, which included a substantially higher proportion of individuals with low levels of body fat also confirmed that higher baseline visceral fat led to greater visceral fat reductions overall. And that we're able to see, as you point out, substantial reductions in both fat, visceral fat in particular, and liver fat, we should remind that the liver fat was pretty substantial. Our visceral fat compartment was a liter versus 5 liters, almost 5x as much visceral fat where we're seeing that reduction.